Accelerating scientific discovery with Co-Scientist

Checked 30 Sept 2026. Open license (CC-BY, CC-BY-SA, CC0, public domain): full text indexed and used in synthesis.

The sources disagree. The gate chose the strictest class (orange). A human review set it to green: “Crossref (publisher, version of record) and Europe PMC both give CC-BY 4.0; OpenAlex and Unpaywall only report other-oa. Reviewed by Fredrik 2026-09-30.”

Abstract Scientific discovery is driven by scientists generating hypotheses for complex problems that undergo rigorous experimental validation. To augment this process, we introduce Co-Scientist, a multi-agent artificial intelligence (AI) system built on Gemini for structured scientific thinking and hypothesis generation. Co-Scientist aims to help scientists discover new original knowledge. Conditioned on their research objectives and previous scientific evidence, it formulates demonstrably novel research hypotheses for experimental verification. The system’s design involves agents continuously generating, critiquing and refining hypotheses accelerated by scaling test-time compute. Key contributions include (1) a multi-agent architecture with an asynchronous task execution framework for flexible compute scaling, and (2) a tournament evolution process for self-improving hypotheses generation. Automated evaluations show continued benefits of test-time compute scaling, improving hypothesis quality over time. Although this is a general-purpose system, we focus the validation in three biomedical applications: drug repurposing; novel-target discovery 1 ; and explaining mechanisms of antimicrobial resistance 2 . Specifically, Co-Scientist helped to identify new drug-repurposing candidates and synergistic combination therapies for acute myeloid leukaemia that were validated through in vitro experiments. These real-world validations demonstrate the potential of Co-Scientist to accelerate scientific discovery and usher in an era of AI-empowered scientists.

• Independent teams have converged on multi-agent, tool-using LLM architectures as the core design pattern for AI-for-science systems: Coscientist (Boiko et al. 2023) pairs GPT-4 with search, code execution and lab automation, Co-Scientist (Gottweis et al. 2026) is a multi-agent system built on Gemini, and the Virtual Lab (Swanson et al. 2024) has an LLM principal investigator guiding specialist agents. Qi et al. 2026's survey argues this convergence is functional, since multi-agent redundancy offers error-checking that can mitigate hallucination and bias. Trace →
• The field has shifted from automating narrow, isolated tasks toward general-purpose systems that span much of the research life cycle. Lu et al. 2026's AI Scientist runs from ideation to peer review, Gottweis et al. 2026 frame Co-Scientist as a general collaborator for scientists, and Huang et al. 2025 present Biomni as a general-purpose biomedical agent rather than a specialist workflow. Trace →
• Gottweis et al. 2026 show that scaling test-time compute—through self-play debate, hypothesis tournaments and an evolution process—continues to improve hypothesis quality over time. They validate Co-Scientist in three biomedical settings of varied complexity: cancer drug repurposing, liver-fibrosis target discovery, and antimicrobial-resistance mechanism identification. Trace →
• Gottweis et al. 2026's Co-Scientist is a Gemini-based multi-agent system in which agents continuously generate, critique and refine hypotheses under scaled test-time compute, using self-play debate, tournaments and evolution; it was validated on drug repurposing for cancer, liver fibrosis target discovery, and antimicrobial resistance mechanisms. Trace →
• Role-specialized multi-agent teams are a convergent design pattern across systems such as Co-Scientist and the Virtual Lab, and Qi et al. 2026's survey articulates the rationale: planners, executors, validators and critics provide structured redundancy and error-checking that may mitigate hallucination and bias. Trace →

• AI for science and agentic researchanchor